Cellvizio pCLE Technology Provides More Accurate IBD Diagnoses, Leads To Better Outcomes

Cellvizio pCLE Technology Provides More Accurate IBD Diagnoses, Leads To Better Outcomes
Cellvizio, a probe-based Confocal Laser Endomicroscopy (pCLE) system that is the flagship product of Paris, France, based Mauna Kea Technologies, should be routinely implemented to improve diagnostic evaluation and management of a number of gastric, intestinal, and biliary (liver) diseases. That's the recommendation of a major consensus report by a team of 26 experts representing research and treatment institutions in the U.S., Europe, and Scandinavia, published in the United European Gastroenterology Journal. In the paper, entitled "Use of probe-based confocal laser endomicroscopy (pCLE) in gastrointestinal applications. A consensus report based on clinical evidence" (Published online before print January 14, 2015, doi: 10.1177/2050640614566066), the coauthors note that use of the Cellvizio technology provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues. Large, international, multi-center clinical trials have demonstrated Cellvizio's ability to help physicians detect disease more accurately in real time, to confirm absence of disease and in making immediate treatment decisions. In addition, Cellvizio can provide benefits at each step of patient management and in multiple indications, including Barrett's Esophagus, Gastric Diseases, Bilio-pancreatic Strictures, Pancreatic Cysts, Colorectal Lesions, Lung Nodules, Urinary Tract Lesions, and Inflammatory Bowel Diseases. The paper outlines suggested roles and uses of pCLE for evaluation and treatment of GI lesions by endoscopists, from a consensus of experts. Its aim is to provide guidance to pCLE users and to other interested parties on standardization of practice, and to sugge
Subscribe or to access all post and page content.